Savara has introduced the launch of aPAP ClearPath, a brand new blood take a look at designed to assist US physicians in diagnosing autoimmune pulmonary alveolar proteinosis (aPAP), a uncommon autoimmune lung situation.
The serum-based take a look at detects autoantibodies in opposition to GM-CSF, that are indicative of the illness.
The aPAP ClearPath take a look at affords a delicate and particular technique for quantifying these autoantibodies in human serum.
Savara chair and CEO Matt Pauls mentioned: “Our dedication to the affected person group is underscored by the introduction of this easy, no-cost blood take a look at that US physicians can use to verify or rule out aPAP.
“With a couple of thousand identified sufferers within the US, we suspect the true prevalence of aPAP could also be underestimated and, much like different uncommon ailments, the introduction of a diagnostic may assist lower the time to prognosis and improve identified prevalence.”
Developed in collaboration with Trillium Well being, a contemporary well being options supplier and a CLIA-certified laboratory, the aPAP ClearPath take a look at is an easy, cost-free and non-invasive immunoassay.
Entry probably the most complete Firm Profiles
in the marketplace, powered by GlobalData. Save hours of analysis. Achieve aggressive edge.
Firm Profile – free
Your obtain e-mail will arrive shortly
We’re assured in regards to the
high quality of our Firm Profiles. Nevertheless, we would like you to take advantage of
choice for your corporation, so we provide a free pattern you can obtain by
submitting the under type
Autoimmune PAP is an unusual lung situation the place there may be an uncommon accumulation of surfactant sediment within the air sacs (alveoli) of the lungs.
It represents about 90% of PAP instances, with an estimated seven identified instances per million within the US. Prevalence charges in different areas are believed to be related or increased.
Savara has initiated a illness consciousness marketing campaign alongside the take a look at to reinforce understanding of aPAP, its main indicators and signs, and the significance of early testing amongst healthcare professionals.
Subsequent yr, the corporate plans to launch a healthcare supplier illness consciousness marketing campaign and introduce a GM-CSF autoantibody blood take a look at in Europe.
College of Florida Pulmonary and Crucial Care Drugs division medication affiliate professor Dr Ali Ataya mentioned: “Schooling and widespread blood testing for aPAP is a vital step in shortening the time to prognosis for sufferers with aPAP, serving to to keep away from misdiagnoses and extra expensive and invasive diagnostic procedures.”